SynthesisOrphanet journal of rare diseases2026
Mortality in octogenarian patients with transthyretin amyloidosis treated with tafamidis: a systematic review and meta-analysis.
Synthesis in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects older adults, and tafamidis has proven efficacy in reducing mortality and hospitalizations in this population. However, its clinical benefit in octogenarians remains uncertain due to limited life expectancy, frailty, and other age-related factors. This meta-analysis evaluates the effect of tafamidis in patients aged ≥ 80 years, aiming to address the gap in evidence regarding the therapy's impact in this population.
methodsA systematic review and meta-analysis were conducted by searching PubMed, Embase, and Cochrane databases for studies comparing tafamidis versus control in patients aged ≥ 80 years with transthyretin amyloidosis. The primary outcome was all-cause mortality. Hazard ratios (HRs) were pooled using a random-effects model, and heterogeneity was assessed using I² statistics.
resultsThree studies with a total of 1,866 participants were included (1 randomized controlled trial, 1 prospective cohort, and 1 retrospective study). The majority (77.3%) of patients received tafamidis, and the mean age was 84 years. Tafamidis was associated with a significant reduction in all-cause mortality (HR: 0.51; 95% CI 0.40-0.67; p < 0.01; I² = 10.3%). Sensitivity analyses confirmed the robustness of this finding. The tafamidis group showed no increased risk of adverse events compared to controls.
conclusionTafamidis significantly reduces all-cause mortality in octogenarian patients with ATTR-CM, supporting its use as a cornerstone therapy in this population. Further randomized controlled trials are needed to validate these findings and optimize treatment strategies in very elderly patients with advanced disease or comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.